# Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

> **NCT06462183** · PHASE1 · RECRUITING · sponsor: **Rgenta Therapeutics Inc** · enrollment: 105 (estimated)

## Conditions studied

- Adenoid Cystic Carcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** RGT-61159

## Key facts

- **NCT ID:** NCT06462183
- **Lead sponsor:** Rgenta Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-19
- **Primary completion:** 2025-12
- **Final completion:** 2027-06
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462183, "Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06462183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*